Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Common Equity (2016 - 2025)

Historic Common Equity for STRATA Skin Sciences (SSKN) over the last 14 years, with Q3 2025 value amounting to $1.3 million.

  • STRATA Skin Sciences' Common Equity fell 8602.28% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 8602.28%. This contributed to the annual value of $5.0 million for FY2024, which is 6081.34% down from last year.
  • Per STRATA Skin Sciences' latest filing, its Common Equity stood at $1.3 million for Q3 2025, which was down 8602.28% from $532000.0 recorded in Q2 2025.
  • STRATA Skin Sciences' Common Equity's 5-year high stood at $26.2 million during Q3 2021, with a 5-year trough of $532000.0 in Q2 2025.
  • Its 5-year average for Common Equity is $15.5 million, with a median of $16.9 million in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 98.74% in 2021, then plummeted by 9440.35% in 2025.
  • STRATA Skin Sciences' Common Equity (Quarter) stood at $25.4 million in 2021, then fell by 14.1% to $21.8 million in 2022, then plummeted by 41.88% to $12.7 million in 2023, then tumbled by 60.81% to $5.0 million in 2024, then crashed by 73.57% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $532000.0 for Q2 2025, and $3.0 million during Q1 2025.